ClinicalTrials.gg

Program

canvuparatide

Also written as “MBX 2109”, “Canvuparatide” and “MBX 2109 (Part A)”.

Its studies are mostly in Hypoparathyroidism · Renal Insufficiency, led by MBX Biosciences.

Furthest: phase 3, since Jul 7, 20264 company-led studies, 1 open or runningNext primary completion: Jan 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
MBX Biosciences41 open or runningphase 3since Jul 7, 2026Dec 2, 2021Jan 2028phase 3 · NCT07699471

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 2, 2021First study: phase 1 study in HealthyFirst studyNCT05158335 · 76 enrolled · United States
  2. Jun 12, 2024Phase 1 study in Renal InsufficiencyNCT06496217 · 25 enrolled · United States
  3. Jun 13, 2024Phase 2 study in HypoparathyroidismNCT06465108 · 64 enrolled · United States, Argentina, Turkey (Türkiye)
  4. Jul 7, 2026Phase 3 study in HypoparathyroidismPhase 3 reachedNCT07699471 · 160 planned · United States, Canada

Ahead

  1. Jan 2028Primary completion: phase 3 study in HypoparathyroidismNCT07699471

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07699471Hypoparathyroidism · United States, Canada3RecruitingJan 2028160
NCT06465108Hypoparathyroidism · United States, Argentina, Turkey (Türkiye)2CompletedMay 23, 202564
NCT06496217Renal Insufficiency · United States1CompletedSep 4, 202525
NCT05158335Healthy · United States1CompletedJun 20, 202376

How it is read

Names in the registry

  • “MBX 2109”, 5 entries
  • “Canvuparatide”, 1 entry
  • “MBX 2109 (Part A)”, 1 entry
  • “MBX 2109 (Part B)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.